Aug 24, 2012, 01.06 PM | Source: Moneycontrol.com
Cadila Healthcare rose more than 2% on Friday as the company has entered into a definitive agreement with Microbix for re-launching of Urokinase, a critical care therapy in North America.
The company had signed a letter of intent with Microbix Biosystems, a biotechnology company commercialising novel technologies to market the Thrombolytic drug, Urokinase in the North America on January 6.
According to a release sent to exchanges in January, the market size for this drug in the US alone is expected to touch USD 400 million by 2020 between three indications pulmonary embolism, catheter clearance and catheter prophylaxis. The same active pharmaceutical ingredient can be used in new and even larger indications in oncology and ophthalmology.
Urokinase was first approved in the US in 1978 for pulmonary embolism (blockage in the arteries supplying blood to the lungs) and coronary occlusion (blockage in the vessels which carry blood in the heart).
At 11:03 hours IST, the share was trading at Rs 894, up 2.30% with volumes of 2,215 equity shares.
Market capitalisation of the company currently stands at Rs 18,304.52 crore.
Rahul Shah of Motilal Oswal is of the view that on
The company had posted a net profit after taxes, m
During the quarter, EBITDA may increase 11 percent
The group has received final approval from the US
Zydus Cadila has received the final approval from
Tata Motors continued it upward movement post yest